Last checked at 30 Apr 2015 07:00
ValiRx Plc
("ValiRx" or the "Company")
VALIRX INVITED TO JOIN LEADING LONDON-BASED AND BRITISH BIOTECH COMPANIES IN THE 'MARKET VISIT' TO THE 2015 BIO INTERNATIONAL CONVENTION IN PHILADELPHIA, WITH SUPPORT FROM THE MAYOR OF LONDON'S 'EXPORT PROGRAMME' AND THE DTI
London (April 30th 2015) - ValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that the Company has been invited to join with leading UK biotechnology and biopharma facing businesses and to participate in the 'Market Visit' to the 2015 BIO International Convention in Philadelphia, Pennsylvania (14-18 June 2015).
The Market Visit has been organised by the Mayor of London's Export Programme, in partnership with UK Trade & Investment (UKTI) to offer London SMEs an opportunity to attend this major industry international event and a chance to partner with the world's leading pharmaceutical and biotechnology companies.
The Mayor's Export Programme delivered in partnership with UKTI and co-funded by the European Regional Development Fund (ERDF), seeks to increase the number of London's SMEs trading internationally by providing them with the requisite expertise, support and funding to start trading in new markets.
Last year's Convention featured more than 1,800 exhibitors and 55 state, regional and country pavilions in an area of over 160,000 square feet. The Convention was visited by attendees from leading biotech companies, top 25 pharma companies and more than 300 academic institutions, including research labs and government agencies.
According to the 2013 Campbell Alliance's Deal Makers' Intentions report, most successful deals in the biopharma industry are a result of partnering events. The 2014 Convention held more than 28,000 partnering meetings between 3,166 companies in 3 days.
Dr Satu Vainikka, CEO of ValiRx, commented: "I am delighted ValiRx has been invited to join an impressive British delegation of biotech businesses attending this major industry event. I look forward to the Company building its profile on the international stage, particularly following our successful poster presentation at the recent American Association for Cancer Research ("AACR") conference in Philadelphia and I look forward to ValiRx expanding its network of relationships to the benefit of our shareholders".
*** ENDS ***
For more information, please contact:
ValiRx plc | Tel: +44 (0)20 3008 4416 |
Dr Satu Vainikka
| www.ValiRx.com |
Cairn Financial Advisers LLP (Nominated Adviser) | Tel: +44 (0)20 7148 7900 |
Liam Murray / Avi Robinson
| |
Daniel Stewart & Company Plc (Broker) | Tel: +44 (0)20 7776 6550 |
Martin Lampshire
| |
Peckwater PR | Tel: +44 (0)7879 458 364 |
Tarquin Edwards | tarquin.edwards@peckwaterpr.co.uk |
Notes for Editors
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company has undertaken to develop a novel and groundbreaking class of therapeutics across a number of fields in oncology and has taken its lead compound, Val201, into Phase I/II clinical trials. The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006.
The Company has a pipeline of other therapeutic drugs, which are currently progressing towards clinical trials. The product focus is in the targeted analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
It actively manages projects within its portfolio as a trading company. The ValiRx business model spreads the risks of life science technology development by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeutics division, with two embedded technologies primarily directed at the treatment of cancers.
2. ValiFinn is the biomarkers and diagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology later in the year to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentially other indications.